The United States District Court for the District of New Jersey has ruled that AstraZeneca's US patent protecting Pulmicort Respules in the US, is invalid. The Court also said that the generic defendants involved in the litigation do not ...
Tags: Pulmicort, Health, Pulmicort Patent